AVM Biotechnology (AVM) has announced the appointment of Janet R. Rea as its new Chief Operating Officer, as it prepares to begin clinical trials for its potentially exciting new molecule. The Seattle-based biotech firm has received FDA permission to begin clinical trials of molecule AVM0703 in the treatment of no-option Non-Hodgkin's Lymphoma, and is applying to begin trials in treating COVID-19 patients, and Ms. Rea will lead operations and regulatory affairs throughout this process.
"I am delighted that Janet Rea will join our team at AVM Biotechnology," said AVM Executive Board Member Dr. Manon Cox. "I know that her passion for quality and her tremendous experience in the transition from development into commercialization is exactly what we need at this crucial time at AVM now that our lead product is moving into the clinic."
Rea, has more than 35 years of leadership experience in clinical development, and comes into the role having most recently served as SVP of Regulatory, Quality and Clinical Affairs at Atossa Therapeutics (Genetics), where her focus was on breast cancer and COVID-19 therapy development. Ms. Rea will also serve as a non-voting member of AVM's Board of Directors.
"I am thrilled and honored to be joining AVM Biotechnology and look forward to working with this distinguished team to make new therapies available," Ms. Rea said.